{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:06:09Z","timestamp":1793361969747,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1053\/j.jvca.2023.01.041","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T02:07:52Z","timestamp":1675735672000},"page":"956-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors"],"prefix":"10.1053","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-8439","authenticated-orcid":false,"given":"Jonathan S.","family":"Auerbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-2489","authenticated-orcid":false,"given":"Hayley B.","family":"Gershengorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar D.","family":"Aljure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lamelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanira D.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaro A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2023.01.041_bib0001","doi-asserted-by":"crossref","first-page":"961","DOI":"10.15585\/mmwr.mm6843a2","article-title":"Diabetes prevalence and incidence among medicare beneficiaries - United States, 2001-2015","volume":"68","author":"Andes","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.jvca.2023.01.041_bib0002","doi-asserted-by":"crossref","DOI":"10.2337\/db20-1579-P","article-title":"1579-P: Prevalence and incidence of obesity and diabetes in the United States, 2011-2017","volume":"69","author":"Nielsen","year":"2020","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2023.01.041_bib0003","doi-asserted-by":"crossref","first-page":"k1497","DOI":"10.1136\/bmj.k1497","article-title":"Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study","volume":"362","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"10.1053\/j.jvca.2023.01.041_bib0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0091270011400604","article-title":"SGLT2 inhibitors: A new emerging therapeutic class in the treatment of type 2 diabetes mellitus","volume":"52","author":"Ghosh","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2023.01.041_bib0005","unstructured":"U.S. Food & Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Accessed December 7, 2022."},{"key":"10.1053\/j.jvca.2023.01.041_bib0006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jvca.2023.01.041_bib0007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12902-022-01126-z","article-title":"The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study","volume":"22","author":"Iwasaki","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1053\/j.jvca.2023.01.041_bib0008","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ALN.0000000000003626","article-title":"Perioperative management of glucose-lowering drugs: Comment","volume":"134","author":"Thiruvenkatarajan","year":"2021","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2023.01.041_bib0009","unstructured":"U.S. Food & Drug Administration. Highlights of Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210874s000lbl.pdf. Accessed September 29, 2022."},{"key":"10.1053\/j.jvca.2023.01.041_bib0010","unstructured":"U.S. Food & Drug Administration. Highlights of Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212614s000lbl.pdf. Accessed September 29, 2022."},{"key":"10.1053\/j.jvca.2023.01.041_bib0011","doi-asserted-by":"crossref","first-page":"742","DOI":"10.34067\/KID.0000412021","article-title":"Real-life prescribing of SGLT2 inhibitors: How to handle the other medications, including glucose-lowering drugs and diuretics","volume":"2","author":"Lam","year":"2021","journal-title":"Kidney360"},{"key":"10.1053\/j.jvca.2023.01.041_bib0012","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1053\/j.jvca.2023.01.041_bib0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/joim.12244","article-title":"Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport","volume":"276","author":"Abdul-Ghani","year":"2014","journal-title":"J Intern Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.jvca.2023.01.041_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2023.01.041_bib0017","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0018","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0019","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0020","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2023.01.041_bib0021","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0022","first-page":"4","volume":"24","author":"McDonagh","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2023.01.041_bib0023","doi-asserted-by":"crossref","first-page":"m4147","DOI":"10.1136\/bmj.m4147","article-title":"Diabetic ketoacidosis with SGLT2 inhibitors","volume":"371","author":"Musso","year":"2020","journal-title":"BMJ"},{"key":"10.1053\/j.jvca.2023.01.041_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature","volume":"12","author":"Diaz-Ramos","year":"2019","journal-title":"Int J Emerg Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association Of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.jvca.2023.01.041_bib0026","first-page":"20","article-title":"A case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery","volume":"7","author":"Osafehinti","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"10.1053\/j.jvca.2023.01.041_bib0027","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcjd.2022.06.007","article-title":"Sodium-glucose cotransporter-2 inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery","volume":"46","author":"Chaudhry","year":"2022","journal-title":"Can J Diabetes"},{"key":"10.1053\/j.jvca.2023.01.041_bib0028","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: A missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1053\/j.jvca.2023.01.041_bib0029","unstructured":"The Society of Thoracic Surgeons National Database. Available at:https:\/\/www.sts.org\/registries\/sts-national-database\/adult-cardiac-surgery-database.Adult cardiac surgier dabase. Accessed October 20, 2022."},{"key":"10.1053\/j.jvca.2023.01.041_bib0030","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2023.01.041_bib0031","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence","volume":"28","author":"Mehta","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1053\/j.jvca.2023.01.041_bib0032","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.athoracsur.2010.07.063","article-title":"Effects of moderate intensity glycemic control after cardiac surgery","volume":"90","author":"Leibowitz","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2023.01.041_bib0033","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.athoracsur.2021.03.043","article-title":"STS Adult Cardiac Surgery Database: 2021 update on outcomes, quality, and research","volume":"111","author":"Bowdish","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2023.01.041_bib0034","unstructured":"Center for Medicare and Medicaid Services. Resources. Available at: https:\/\/qualitynet.cms.gov\/inpatient\/measures\/psi\/resources. Accessed October 20, 2022"},{"key":"10.1053\/j.jvca.2023.01.041_bib0035","unstructured":"Department of Health and Human Services Centers for Medicare and Medicaid Services 42 CFR Parts 412, 413, 425, 455, and 495 [CMS-1752-F and CMS-1762-F] RINs 0938-AU44 and 0938-AU56 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2022 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Changes to Medicaid Provider Enrollment; and Changes to the Medicare Shared Savings Program. Available at:https:\/\/www.federalregister.gov\/documents\/2021\/08\/13\/2021-16519\/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the. Accessed October 20, 2022."},{"key":"10.1053\/j.jvca.2023.01.041_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.884144","article-title":"Outcomes of postoperative delirium in patients undergoing cardiac surgery: A systematic review and meta-analysis","volume":"9","author":"Lin","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0037","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.21037\/atm-21-5160","article-title":"Risk factors for delirium after coronary artery bypass grafting in elderly patients","volume":"9","author":"Li","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.jvca.2023.01.041_bib0038","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jtcvs.2020.07.028","article-title":"Delirium definition influences prediction of functional survival in patients one-year postcardiac surgery","volume":"163","author":"Dubiel","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2023.01.041_bib0039","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.2337\/dc21-S015","article-title":"15. Diabetes care in the hospital: Standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077023000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077023000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:04:28Z","timestamp":1760947468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077023000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1053077023000617"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2023.01.041","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2023.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}